PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23760276-10 2013 NMR and surface plasmon resonance data show that three CaM antagonists (N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, tamoxifen, and trifluoperazine) greatly inhibit Fas-CaM interactions by blocking the Fas-binding site on CaM. Tamoxifen 125-134 calmodulin 1 Homo sapiens 55-58 2994657-1 1985 The calmodulin antagonists trifluoperazine, chlorpromazine, perphenazine, promazine, tamoxifen and the naphthalene sulfonamide derivatives W7 and W13 increased the level of 32P-incorporation into human platelet PIP and PIP2. Tamoxifen 85-94 calmodulin 1 Homo sapiens 4-14 6320825-0 1984 Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Tamoxifen 0-9 calmodulin 1 Homo sapiens 15-25 6320825-2 1984 In this paper, we present evidence that tamoxifen is an antagonist of calmodulin, a major cellular calcium receptor and calcium dependent regulator of many cellular processes. Tamoxifen 40-49 calmodulin 1 Homo sapiens 70-80 6320825-3 1984 Our data showed that tamoxifen inhibited the activation of phosphodiesterase by calmodulin. Tamoxifen 21-30 calmodulin 1 Homo sapiens 80-90 6320825-5 1984 Kinetic analysis demonstrated that tamoxifen is a competitive inhibitor of calmodulin in the activation of this enzyme. Tamoxifen 35-44 calmodulin 1 Homo sapiens 75-85 6320825-6 1984 It could be speculated that the antagonism of calmodulin by tamoxifen may be one of the mechanisms responsible for its pharmacological actions. Tamoxifen 60-69 calmodulin 1 Homo sapiens 46-56 2706627-1 1989 Tamoxifen and other structurally related nonsteroidal antiestrogens possess properties in addition to their estrogen antagonist activity including inhibition of both calmodulin and protein kinase C. The present studies were designed to test whether the estrogen-reversible (estrogen receptor mediated) and estrogen-irreversible effects of nonsteroidal antiestrogens on cell cycle progression in vitro were mediated at the same or different points within the cell cycle and if the estrogen-irreversible effects coincided temporally with that of a calmodulin antagonist, R24571. Tamoxifen 0-9 calmodulin 1 Homo sapiens 166-176 2706627-1 1989 Tamoxifen and other structurally related nonsteroidal antiestrogens possess properties in addition to their estrogen antagonist activity including inhibition of both calmodulin and protein kinase C. The present studies were designed to test whether the estrogen-reversible (estrogen receptor mediated) and estrogen-irreversible effects of nonsteroidal antiestrogens on cell cycle progression in vitro were mediated at the same or different points within the cell cycle and if the estrogen-irreversible effects coincided temporally with that of a calmodulin antagonist, R24571. Tamoxifen 0-9 calmodulin 1 Homo sapiens 546-556 3022916-1 1986 The triphenylethylene antiestrogen tamoxifen has been shown previously to inhibit both calmodulin and protein kinase C activities, which are involved in the control of cell proliferation. Tamoxifen 35-44 calmodulin 1 Homo sapiens 87-97 20172594-5 2010 Here we show that CaM antagonists N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W7), tamoxifen (TMX), and trifluoperazine (TFP) induce apoptotic events in human platelets, including depolarization of mitochondrial inner transmembrane potential, caspase-3 activation, and phosphatidylserine exposure. Tamoxifen 92-101 calmodulin 1 Homo sapiens 18-21 20172594-5 2010 Here we show that CaM antagonists N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W7), tamoxifen (TMX), and trifluoperazine (TFP) induce apoptotic events in human platelets, including depolarization of mitochondrial inner transmembrane potential, caspase-3 activation, and phosphatidylserine exposure. Tamoxifen 103-106 calmodulin 1 Homo sapiens 18-21 14578204-8 2003 The combination of IFN-gamma and CaM antagonists, including tamoxifen, may be a potential therapeutic modality for cholangiocarcinoma and possibly other malignancies. Tamoxifen 60-69 calmodulin 1 Homo sapiens 33-36 15965236-4 2005 We show here that a 3-h treatment of mouse osteoclasts with either of the calmodulin antagonists, tamoxifen or trifluoperazine, induces osteoclast apoptosis dose-dependently. Tamoxifen 98-107 calmodulin 1 Homo sapiens 74-84 8885989-3 1996 By Western blotting and [125I]tamoxifen aziridine covalent labeling we found that this CaM-induced loss is not associated with a disappearance of the ER protein. Tamoxifen 30-39 calmodulin 1 Homo sapiens 87-90 14667143-1 2003 Tamoxifen inhibits bone resorption by disrupting calmodulin-dependent processes. Tamoxifen 0-9 calmodulin 1 Homo sapiens 49-59 14667143-7 2003 Furthermore, exogenous calmodulin blocked tamoxifen, but not bIM, -dependent inhibition of acid transport. Tamoxifen 42-51 calmodulin 1 Homo sapiens 23-33 10625668-4 2000 The pro-apoptotic effect of gp160 expression is blocked by two calmodulin antagonists, tamoxifen and trifluoperazine. Tamoxifen 87-96 calmodulin 1 Homo sapiens 63-73 11206583-0 2000 Tamoxifen inhibits phorbol ester stimulated osteoclastic bone resorption: an effect mediated by calmodulin. Tamoxifen 0-9 calmodulin 1 Homo sapiens 96-106 11206583-1 2000 Tamoxifen inhibits bone resorption by disrupting calmodulin-dependent processes. Tamoxifen 0-9 calmodulin 1 Homo sapiens 49-59 9037257-1 1997 Previously, two antiestrogens estradiol derivatives (3 and 4) bearing the basic side chain of tamoxifen were shown to impede the binding of the estrogen receptor (ER) to calmodulin (CaM)-Sepharose. Tamoxifen 94-103 calmodulin 1 Homo sapiens 170-180 9037257-1 1997 Previously, two antiestrogens estradiol derivatives (3 and 4) bearing the basic side chain of tamoxifen were shown to impede the binding of the estrogen receptor (ER) to calmodulin (CaM)-Sepharose. Tamoxifen 94-103 calmodulin 1 Homo sapiens 182-185 12619929-4 2003 We compared the effects of cyclosporine A and the calmodulin antagonist, tamoxifen, on bone resorption by avian osteoclasts. Tamoxifen 73-82 calmodulin 1 Homo sapiens 50-60 12619929-9 2003 In contrast, direct addition of tamoxifen to membranes inhibits acid transport activity, an effect that can be prevented by addition of exogenous calmodulin. Tamoxifen 32-41 calmodulin 1 Homo sapiens 146-156 11278648-6 2001 However, incubation of the cells with tamoxifen enhanced by 5-10-fold the association of calmodulin with the estrogen receptor and increased the total cellular content of estrogen receptors by 1.5-2-fold. Tamoxifen 38-47 calmodulin 1 Homo sapiens 89-99 11206583-7 2000 Tamoxifen and trifluoperazine inhibited PMA-dependent increases in bone resorption and calmodulin by 85 +/- 10%. Tamoxifen 0-9 calmodulin 1 Homo sapiens 87-97 11206583-9 2000 In conclusion, the data suggest that protein kinase C negatively regulates calmodulin expression and support the hypothesis that the effects of both phorbol esters and tamoxifen on osteoclast activity is mediated by calmodulin. Tamoxifen 168-177 calmodulin 1 Homo sapiens 216-226 9464453-2 1997 TMX affected the activation of NOS by calmodulin, as it not only inhibited L-arginine oxidation to nitric oxide and L-citrulline but also NADPH oxidation and calmodulin-dependent cytochrome c reduction catalyzed by nNOS. Tamoxifen 0-3 calmodulin 1 Homo sapiens 38-48 9464453-2 1997 TMX affected the activation of NOS by calmodulin, as it not only inhibited L-arginine oxidation to nitric oxide and L-citrulline but also NADPH oxidation and calmodulin-dependent cytochrome c reduction catalyzed by nNOS. Tamoxifen 0-3 calmodulin 1 Homo sapiens 158-168 9062408-3 1997 Interestingly, the non-steroidal anti-oestrogen tamoxifen (which also has calmodulin antagonist activity), used in the treatment of breast cancer and now in metastatic cutaneous melanoma, can inhibit the attachment of normal and neoplastic cells to ECM. Tamoxifen 48-57 calmodulin 1 Homo sapiens 74-84 9062408-5 1997 We examined the ability of the specific calmodulin antagonist J8, tamoxifen and its two major metabolites, N-desmethyltamoxifen (N-des) and 4-hydroxytamoxifen (4-OH), as well as the pure anti-oestrogen ICI 182,780 and 17beta-oestradiol to inhibit invasion of the human cutaneous melanoma cell line, A375-SM, uveal melanoma cells and uveal melanocytes. Tamoxifen 66-75 calmodulin 1 Homo sapiens 40-50 7855067-6 1994 We report that six ocular melanoma cell lines established from choroidal melanoma tumours showed rapid attachment to a range of substrates and that this attachment can be significantly reduced by an experimental calmodulin antagonist (J8) and by tamoxifen. Tamoxifen 246-255 calmodulin 1 Homo sapiens 212-222 8647856-5 1996 At these concentrations ICI 182780, like tamoxifen, inhibits calmodulin-stimulated cyclic nucleotide phosphodiesterase activity. Tamoxifen 41-50 calmodulin 1 Homo sapiens 61-71 8647856-11 1996 Our findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-associated target(s), probably similar or related to calmodulin antagonist targets. Tamoxifen 27-36 calmodulin 1 Homo sapiens 146-156 7669076-0 1995 Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Tamoxifen 82-91 calmodulin 1 Homo sapiens 68-78 7923990-9 1994 Similarly tamoxifen (25 microM), which has calmodulin antagonist activity in vitro, reduced attachment to 55%. Tamoxifen 10-19 calmodulin 1 Homo sapiens 43-53 7945433-0 1994 Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Tamoxifen 14-23 calmodulin 1 Homo sapiens 33-43 7945433-2 1994 The substitution of an extra methyl group into the ring-fused analogue, at a position which the ethyl group of tamoxifen can occupy in one of its conformations, restored the calmodulin inhibition. Tamoxifen 111-120 calmodulin 1 Homo sapiens 174-184 7945433-3 1994 Also, the replacement of the tamoxifen ethyl group by methyl diminishes calmodulin inhibition. Tamoxifen 29-38 calmodulin 1 Homo sapiens 72-82 7945433-4 1994 Direct interaction of these tamoxifen analogues with calmodulin was demonstrated through the use of the fluorescent probe, 2-p-toluidinyl-naphthalene-6-sulfonic acid (TNS). Tamoxifen 28-37 calmodulin 1 Homo sapiens 53-63 7945433-5 1994 These findings lead to the conclusion that tamoxifen binds to calmodulin in a conformation not accessible to the fused analogue and therefore likely to be different to that which binds to the ER. Tamoxifen 43-52 calmodulin 1 Homo sapiens 62-72 7497456-6 1995 Combination of TMX with non-toxic calmodulin inhibitors may increase the preventive and therapeutic effects of TMX. Tamoxifen 111-114 calmodulin 1 Homo sapiens 34-44 7830266-0 1995 Rationally designed analogues of tamoxifen with improved calmodulin antagonism. Tamoxifen 33-42 calmodulin 1 Homo sapiens 57-67 7830266-1 1995 Computerized molecular modeling studies on the interactions of the antiestrogen tamoxifen (1) and its analogues bound to the calcium-binding protein calmodulin have guided the rational design of more potent antagonists. Tamoxifen 80-89 calmodulin 1 Homo sapiens 149-159 8075251-2 1994 F1 is the Ca(2+)-calmodulin-dependent phosphodiesterase and its activity is inhibited by calmodulin antagonists (W-7, TFP, tamoxifen) via a mechanism typical for the majority of Ca(2+)-calmodulin-dependent enzymes. Tamoxifen 123-132 calmodulin 1 Homo sapiens 17-27 8075251-2 1994 F1 is the Ca(2+)-calmodulin-dependent phosphodiesterase and its activity is inhibited by calmodulin antagonists (W-7, TFP, tamoxifen) via a mechanism typical for the majority of Ca(2+)-calmodulin-dependent enzymes. Tamoxifen 123-132 calmodulin 1 Homo sapiens 89-99 8075251-2 1994 F1 is the Ca(2+)-calmodulin-dependent phosphodiesterase and its activity is inhibited by calmodulin antagonists (W-7, TFP, tamoxifen) via a mechanism typical for the majority of Ca(2+)-calmodulin-dependent enzymes. Tamoxifen 123-132 calmodulin 1 Homo sapiens 89-99 8129752-0 1994 Estradiol derivatives bearing the side-chain of tamoxifen antagonize the association between the estrogen receptor and calmodulin. Tamoxifen 48-57 calmodulin 1 Homo sapiens 119-129 8129752-2 1994 The antiestrogen tamoxifen impedes this association suggesting that the latter would play an important role in CaM-dependent enzymatic catalyses. Tamoxifen 17-26 calmodulin 1 Homo sapiens 111-114 7867020-1 1994 Recent cumulative data have shown that tamoxifen and its metabolites inhibit the activation of cAMP phosphodiesterase by calmodulin (CaM). Tamoxifen 39-48 calmodulin 1 Homo sapiens 121-131 7867020-1 1994 Recent cumulative data have shown that tamoxifen and its metabolites inhibit the activation of cAMP phosphodiesterase by calmodulin (CaM). Tamoxifen 39-48 calmodulin 1 Homo sapiens 133-136 7867020-3 1994 Tamoxifen (TAM) enhanced the fluorescence of TNS bound to CaM and shifted the emission maximum to lower wavelengths. Tamoxifen 0-9 calmodulin 1 Homo sapiens 58-61 7867020-3 1994 Tamoxifen (TAM) enhanced the fluorescence of TNS bound to CaM and shifted the emission maximum to lower wavelengths. Tamoxifen 11-14 calmodulin 1 Homo sapiens 58-61 7867020-6 1994 These results suggest that TAM bound to CaM at sites distinct from those of TNS and induced a change in TNS environment. Tamoxifen 27-30 calmodulin 1 Homo sapiens 40-43 7867020-7 1994 Interaction of TAM metabolites with CaM depended on the degree of alteration of the dimethylaminoethoxy side-chain. Tamoxifen 15-18 calmodulin 1 Homo sapiens 36-39 1661414-14 1991 The effect of trifluoperazine and tamoxifen does not involve changes in transmembrane calcium movements but could be mediated by their inhibition of calmodulin-mediated reactions within the cell. Tamoxifen 34-43 calmodulin 1 Homo sapiens 149-159 1418821-0 1992 A note on the conformational flexibility of the antiestrogenic drug tamoxifen: preferred conformations in the free state and bound to the protein calmodulin. Tamoxifen 68-77 calmodulin 1 Homo sapiens 146-156 1418821-4 1992 These differences have implications for the interactions of tamoxifen with the calcium-binding protein calmodulin; relevant results from a molecular-modelling study of this protein-drug complex are presented. Tamoxifen 60-69 calmodulin 1 Homo sapiens 103-113 1590802-2 1992 Triphenylethylene antiestrogens (tamoxifen family) with strong antagonistic activity against the calmodulin-dependent c-AMP phosphodiesterase largely reduced the binding of the receptor. Tamoxifen 33-42 calmodulin 1 Homo sapiens 97-107 1403784-0 1992 Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. Tamoxifen 0-9 calmodulin 1 Homo sapiens 98-108 1322985-0 1992 A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin. Tamoxifen 77-86 calmodulin 1 Homo sapiens 144-154 1322985-1 1992 The interactions of the antiestrogenic drug tamoxifen with the calcium-binding protein calmodulin have been studied by computerized molecular modeling methods. Tamoxifen 44-53 calmodulin 1 Homo sapiens 87-97 2165403-0 1990 Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Tamoxifen 102-111 calmodulin 1 Homo sapiens 31-41 2165403-1 1990 The ability of a variety of analogues of tamoxifen to inhibit calmodulin dependent cyclic AMP phosphodiesterase has been determined. Tamoxifen 41-50 calmodulin 1 Homo sapiens 62-72 2158363-0 1990 Inhibition of protein kinase C and calmodulin by the geometric isomers cis- and trans-tamoxifen. Tamoxifen 86-95 calmodulin 1 Homo sapiens 35-45 2158363-3 1990 Therapeutic concentrations of trans-tamoxifen inhibit protein kinase C (PKC) and calmodulin-dependent enzymes. Tamoxifen 30-45 calmodulin 1 Homo sapiens 81-91 2158363-4 1990 PKC and calmodulin play critical roles in growth regulation, and there is evidence that inhibition of PKC and calmodulin by trans-tamoxifen may contribute to the antitumor activity of the drug in vivo. Tamoxifen 124-139 calmodulin 1 Homo sapiens 110-120